Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 1, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: European Respiratory Society (ERS) International Congress 2022 – September 4-6, 2022 Title: Silencing MMP7
View HTML
Toggle Summary Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 17, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results
- Conference Call and Webcast Today, August 4, 2022 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Aug. 4, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2022 . The company is hosting a conference call today,
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 20, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2022 , at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 third quarter ended June 30, 2022 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 8, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 1, 2022 , the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 34
View HTML
Toggle Summary Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 5, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in two Phase 1/2a clinical trials of ARO-MUC5AC and ARO-RAGE, the company’s investigational RNA interference (RNAi) therapeutics designed to reduce
View HTML
Toggle Summary Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
Fibrosis regression observed in 58% (7 of 12) of patients receiving 200 mg fazirsiran Median reduction of 83% of Z-AAT accumulation in the liver Reduction of 69% in histologic globule burden Substantial and sustained improvements in clinically relevant biomarkers of liver health     Osaka, JAPAN,
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming June 2022 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 7, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies Healthcare Conference – June 8-10, 2022 Type: Fireside chat presentation Presenter: Vincent Anzalone ,
View HTML
Toggle Summary Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics
PASADENA, Calif. --(BUSINESS WIRE)--May 26, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is hosting a pulmonary research & development (R&D) Day today in New York City to discuss its emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates that leverage its
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results
- Conference Call and Webcast Today, May 10, 2022 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--May 10, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2022 . The company is hosting a conference call today,
View HTML